140 related articles for article (PubMed ID: 26369760)
1. [Classification of cell-based medicinal products and legal implications: An overview and an update].
Scherer J; Flory E
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1201-6. PubMed ID: 26369760
[TBL] [Abstract][Full Text] [Related]
2. Emerging technologies for quality control of cell-based, advanced therapy medicinal products.
Zia S; Pizzuti V; Paris F; Alviano F; Bonsi L; Zattoni A; Reschiglian P; Roda B; Marassi V
J Pharm Biomed Anal; 2024 Aug; 246():116182. PubMed ID: 38772202
[TBL] [Abstract][Full Text] [Related]
3. The evolving regulatory system of advanced therapy medicinal products in China: a documentary analysis using the World Health Organization Global Benchmarking Tool standards.
Shi J; Chen X; Hu H; Ung COL
Cytotherapy; 2024 Apr; ():. PubMed ID: 38739075
[TBL] [Abstract][Full Text] [Related]
4. The expanding role of blood and tissue establishments in the development of advanced therapy medicinal products.
Horan A; Warreth S; Hervig T; Waters A
Cytotherapy; 2024 May; 26(5):524-530. PubMed ID: 38441513
[TBL] [Abstract][Full Text] [Related]
5. A regulatory perspective of clinical trial applications for biological products with particular emphasis on Advanced Therapy Medicinal Products (ATMPs).
Jones DR; McBlane JW; McNaughton G; Rajakumaraswamy N; Wydenbach K
Br J Clin Pharmacol; 2013 Aug; 76(2):203-9. PubMed ID: 23216470
[TBL] [Abstract][Full Text] [Related]
6. The Relevance of Advanced Therapy Medicinal Products in the Field of Transplantation and the Need for Academic Research Access: Overcoming Bottlenecks and Claiming a New Time.
Piemonti L; Scholz H; de Jongh D; Kerr-Conte J; van Apeldoorn A; Shaw JAM; Engelse MA; Bunnik E; Mühlemann M; Pal-Kutas K; Scott WE; Magalon J; Kugelmeier P; Berishvili E
Transpl Int; 2023; 36():11633. PubMed ID: 37822447
[TBL] [Abstract][Full Text] [Related]
7. ATMP Environmental Exposure Assessment in European Healthcare Settings: A Systematic Review of the Literature.
Damerval M; Fagnoni-Legat C; Louvrier A; Fischer S; Limat S; Clairet AL; Nerich V; Madelaine I; Kroemer M
Front Med (Lausanne); 2021; 8():713047. PubMed ID: 34926483
[TBL] [Abstract][Full Text] [Related]
8. Regulatory and Scientific Advancements in Gene Therapy: State-of-the-Art of Clinical Applications and of the Supporting European Regulatory Framework.
Carvalho M; Sepodes B; Martins AP
Front Med (Lausanne); 2017; 4():182. PubMed ID: 29124055
[TBL] [Abstract][Full Text] [Related]
9. Two Decades of Global Progress in Authorized Advanced Therapy Medicinal Products: An Emerging Revolution in Therapeutic Strategies.
Ramezankhani R; Torabi S; Minaei N; Madani H; Rezaeiani S; Hassani SN; Gee AP; Dominici M; Silva DN; Baharvand H; Hajizadeh-Saffar E
Front Cell Dev Biol; 2020; 8():547653. PubMed ID: 33392179
[TBL] [Abstract][Full Text] [Related]
10. Academic challenges on advanced therapy medicinal products' development: a regulatory perspective.
Olesti E; Nuevo Y; Bachiller M; Guillen E; Bascuas J; Varea S; Saez-Peñataro J; Calvo G
Cytotherapy; 2024 Mar; 26(3):221-230. PubMed ID: 38260921
[TBL] [Abstract][Full Text] [Related]
11. "Regulatory Sandboxes" Could Solve the Regulatory Problems Encountered in Europe and Arising from Innovation in Biological Medicinal Products.
Guerriaud M
Pharmaceut Med; 2024 Jan; 38(1):19-23. PubMed ID: 38070124
[TBL] [Abstract][Full Text] [Related]
12. Regulatory Framework, Challenges, and Initial Strategic Planning for Advanced Therapy Products (PTAs) Development in Brazil.
Fachel FNS; Schuh RS; Grudzinski PB; Teixeira HF; Baldo G; Matte U
Ther Innov Regul Sci; 2024 Jan; 58(1):21-33. PubMed ID: 37815738
[TBL] [Abstract][Full Text] [Related]
13. Defining a Regulatory Strategy for ATMP/Aerosol Delivery Device Combinations in the Treatment of Respiratory Disease.
Woods N; MacLoughlin R
Pharmaceutics; 2020 Sep; 12(10):. PubMed ID: 32993197
[TBL] [Abstract][Full Text] [Related]
14. Advanced Therapy Medicinal Products as Potential Therapeutic Strategy against COVID-19 and Immune-Related Disorders.
Mallis P; Michalopoulos E; Stavropoulos-Giokas C
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474324
[TBL] [Abstract][Full Text] [Related]
15. [Advanced therapy medicinal products' (ATMP) pharmaceutical circuit in France: Current situation and outlook].
Fabri B; Sicard G; Gauthier-Villano L; Pourroy B
Ann Pharm Fr; 2023 Nov; 81(6):1038-1053. PubMed ID: 37075974
[TBL] [Abstract][Full Text] [Related]
16. Polish regulatory system regarding ATMP hospital exemptions.
Pachocki J; Verter F
Front Immunol; 2024; 15():1379134. PubMed ID: 38803487
[TBL] [Abstract][Full Text] [Related]
17. Remuneration of donors for cell and gene therapies: an update on the principles and perspective of the World Marrow Donor Association.
Hamad L; Ahmed SM; van Eerden E; van Walraven SM; ; Machin L
Bone Marrow Transplant; 2024 May; 59(5):580-586. PubMed ID: 38396211
[TBL] [Abstract][Full Text] [Related]
18. A management model in blood, tissue and cell establishments to ensure rapid and sustainable patient access to advanced therapy medicinal products in Europe.
Delgadillo J; Kerkelä E; Waters A; Akker EVD; Lechanteur C; Baudoux E; Gardiner N; De Vos J; Vives J
Cytotherapy; 2023 Dec; 25(12):1259-1264. PubMed ID: 37737767
[TBL] [Abstract][Full Text] [Related]
19. A roadmap towards a human-centric safety assessment of advanced therapy medicinal products.
Chien HT; de Leeuw VC; van Esterik JCJ; Russel FGM; Kienhuis AS; Theunissen PT; van Meer P
Regul Toxicol Pharmacol; 2024 Jun; 150():105631. PubMed ID: 38648873
[TBL] [Abstract][Full Text] [Related]
20. Forging the Fate of Cellular Therapies for Cardiovascular Disease.
Simari RD
Circ Res; 2017 Jun; 120(12):1871-1873. PubMed ID: 28596173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
